Streetbeat News

Revenues

CVS

Five analysts have recently reviewed CVS Health (NYSE:CVS), showing a mix of bullish and somewhat bullish sentiments, with a shift towards more conservative ratings in the last 30 days. The average 12-month price target for CVS is now $90.4, down 3.83% from the previous average, with targets ranging from $84.00 to $99.00. CVS Health's financial performance is strong, with significant revenue growth, high net margin, and effective debt management, positioning it well in the healthcare sector.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 2:00 pm

PDCO

Patterson Cos (NASDAQ:PDCO) has been analyzed by 5 analysts, showing a mix of somewhat bullish and indifferent ratings. The average 12-month price target is now $33.00, down from $36.75, indicating a 10.2% decrease. Analysts from Leerink Partners, Goldman Sachs, Piper Sandler, and Morgan Stanley have adjusted their ratings and price targets, reflecting changes in market dynamics and company performance. Patterson Cos, a leading dental and animal health distributor, shows strong financial health with notable revenue growth, net margin, ROE, and ROA, despite a lower market capitalization compared to industry peers.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 2:00 pm

BABA

NVDA

RIVN

TSLA

Cryptocurrencies trade mixed as Dogecoin mirrors 2023 bull market patterns, and Bitcoin's potential post-halving correction could target $40K. Rivian rebounds in premarket trading. Analysts predict a pause in US stock rally and discuss potential impacts of a second Trump presidency. International tensions rise with US-China relations and covert operations in Ukraine. Tech sector sees Nvidia's upside potential and Alibaba's optimism, while electric vehicle companies like Tesla and Rivian make headlines. Broadcom nears a strategic sale, and financial deals include Ant Group's acquisition of Credit Suisse's China unit.

Portfolio Pulse from Akanksha Bakshi

February 26, 2024 | 1:46 pm

CNEY

CN Energy Group has announced its preliminary revenue forecast for Q1 2024, estimating revenues to be between $21.0M and $22.0M.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:42 pm

SPY

USA Building Permits for the month were reported at 1.489M, slightly above the estimated 1.470M but below the previous month's 1.493M.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:35 pm

SPY

USA Building Permits for the month showed a decrease of 0.3%, which is better than the estimated -1.5% and a decline from the previous 1.8%.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:35 pm

BOF

BranchOut Food Inc. (NASDAQ:BOF), a food technology company, announced an expansion of its relationship with the nation's largest warehouse club due to exceptional sales of its Pineapple Chips in California. The expansion includes two new orders worth approximately $900,000 for Q3 2024, extending the product's reach to the Northern California Region and seven additional states in the Southeast. This follows a successful product launch in the Bay Area and Southern California regions.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:24 pm

COST

FRPT

WMT

As of Feb. 26, 2024, Freshpet, Inc. (FRPT), Walmart Inc. (WMT), and Costco Wholesale Corporation (COST) in the consumer staples sector are considered overbought based on their RSI values, indicating potential short-term performance concerns. Freshpet's recent earnings beat and Walmart's Q4 FY24 sales growth have contributed to their stock gains, while Costco's January sales increase supports its positive momentum.

Portfolio Pulse from Avi Kapoor

February 26, 2024 | 1:18 pm

AHT

Ashford Hospitality Trust, Inc. (AHT) is advancing its plan to pay off its strategic financing by January 2026 through asset sales, mortgage debt refinancings, and capital offerings. The company has agreements for the sale of six assets totaling over $220 million and is in various stages of marketing additional assets. This is part of AHT's broader strategy to manage its financing obligations.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:17 pm

MTNB

Matinas BioPharma announced updates on its MAT2203 Compassionate/Expanded Use Access Program, reporting complete clinical resolution in all 5 patients who completed treatment for serious fungal infections. The program has enrolled 19 patients with various invasive fungal infections. Additionally, patients who switched to MAT2203 from AmBisome due to renal toxicity experienced a reversal of renal impairment.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:05 pm